Augustine Therapeutics is pioneering a new era in HDAC6-targeted drug development, focusing on selective inhibition of HDAC6 for treating chronic diseases, particularly in neuromuscular and cardiometabolic disorders
Augustine Therapeutics is pioneering a new era in HDAC6-targeted drug development, focusing on selective inhibition of HDAC6 for treating chronic diseases, particularly in neuromuscular and cardiometabolic disorders.